ArticleOncotarget2018
Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis.Scientific reports · 2021Trial
- A Latent Autoantibody Axis Associated with Vascular Vulnerability in Ischemic Stroke: Integrated Statistical and Machine-Learning Analysis.International journal of molecular sciences · 2026Article
- Oncogenic role of RNA-binding protein GNL2 in glioma: Promotion of tumor development through enhancing protein synthesis.Oncology letters · 2024Article
- Combination of high anti-SKI and low anti-TMED5 antibody levels is preferable prognostic factor in esophageal carcinoma.Cancer science · 2024Article
- Serum anti-PCK1 antibody levels are a prognostic factor for patients with diabetes mellitus.BMC endocrine disorders · 2023Article
- Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer.Frontiers in cardiovascular medicine · 2023Article
- Identification of Important Modules and Hub Gene in Chronic Kidney Disease Based on WGCNA.Journal of immunology research · 2022Article
- Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction.Scientific reports · 2021Article
- Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers.Molecular and clinical oncology · 2021Article
- Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke.BMC medicine · 2021Article
- Anti-FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer.Cancer science · 2021Article
- Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.Frontiers in oncology · 2021Article
- Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases.Cancer science · 2020Article
- Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.International journal of molecular medicine · 2020Article
- Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases.Heliyon · 2020Article
- Anti-FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma.Cancer science · 2019Article
- Elevation of Autoantibody in Patients with Ischemic Stroke.Neurologia medico-chirurgica · 2018Review
- Serum anti‑TSTD2 antibody as a biomarker for atherosclerosis‑induced ischemic stroke and chronic kidney disease.Medicine internationalArticle
- Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisease specific autoantibodies have been detected in the sera of patients with atherosclerosis-related diseases, such as cerebral infarction, cardiovascular disease. In the present study, we aimed to identify novel autoantibodies responsible for transient ischemic attack (TIA), a prodromal condition for cerebral infarction.
methodsTo identify candidate antigens, we screened a human aortic endothelial cell cDNA library using sera from 20 patients with TIA. Serum antibody levels were measured using amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) in 2 independent patient/healthy donor (HD) cohorts (
resultsFirst screening identified 3 candidate antigens. Of these, programmed cell death 11 (PDCD11) was determined to be associated with stroke (
conclusionSerum PDCD11-Ab level may serve as a potential biomarker for TIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.